ResMed (RMD) Competitors

$218.57
-1.40 (-0.64%)
(As of 05/17/2024 ET)

RMD vs. BAX, DXCM, PODD, TFX, GMED, BDX, BSX, SYK, WST, and SWAV

Should you be buying ResMed stock or one of its competitors? The main competitors of ResMed include Baxter International (BAX), DexCom (DXCM), Insulet (PODD), Teleflex (TFX), Globus Medical (GMED), Becton, Dickinson and Company (BDX), Boston Scientific (BSX), Stryker (SYK), West Pharmaceutical Services (WST), and Shockwave Medical (SWAV). These companies are all part of the "surgical & medical instruments" industry.

ResMed vs.

ResMed (NYSE:RMD) and Baxter International (NYSE:BAX) are both large-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their earnings, institutional ownership, valuation, risk, media sentiment, dividends, community ranking, profitability and analyst recommendations.

Baxter International has higher revenue and earnings than ResMed. Baxter International is trading at a lower price-to-earnings ratio than ResMed, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
ResMed$4.22B7.60$897.56M$6.5133.57
Baxter International$14.81B1.21$2.66B$5.206.78

Baxter International received 313 more outperform votes than ResMed when rated by MarketBeat users. Likewise, 66.24% of users gave Baxter International an outperform vote while only 52.93% of users gave ResMed an outperform vote.

CompanyUnderperformOutperform
ResMedOutperform Votes
415
52.93%
Underperform Votes
369
47.07%
Baxter InternationalOutperform Votes
728
66.24%
Underperform Votes
371
33.76%

ResMed has a net margin of 20.91% compared to Baxter International's net margin of 17.79%. ResMed's return on equity of 24.43% beat Baxter International's return on equity.

Company Net Margins Return on Equity Return on Assets
ResMed20.91% 24.43% 15.70%
Baxter International 17.79%18.47%4.91%

55.0% of ResMed shares are held by institutional investors. Comparatively, 90.2% of Baxter International shares are held by institutional investors. 1.2% of ResMed shares are held by insiders. Comparatively, 0.2% of Baxter International shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

ResMed pays an annual dividend of $1.92 per share and has a dividend yield of 0.9%. Baxter International pays an annual dividend of $1.16 per share and has a dividend yield of 3.3%. ResMed pays out 29.5% of its earnings in the form of a dividend. Baxter International pays out 22.3% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years. Baxter International is clearly the better dividend stock, given its higher yield and lower payout ratio.

ResMed presently has a consensus target price of $202.80, indicating a potential downside of 7.22%. Baxter International has a consensus target price of $45.73, indicating a potential upside of 29.72%. Given Baxter International's higher probable upside, analysts plainly believe Baxter International is more favorable than ResMed.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
ResMed
0 Sell rating(s)
3 Hold rating(s)
7 Buy rating(s)
0 Strong Buy rating(s)
2.70
Baxter International
0 Sell rating(s)
8 Hold rating(s)
2 Buy rating(s)
0 Strong Buy rating(s)
2.20

In the previous week, ResMed had 3 more articles in the media than Baxter International. MarketBeat recorded 12 mentions for ResMed and 9 mentions for Baxter International. ResMed's average media sentiment score of 0.95 beat Baxter International's score of 0.35 indicating that ResMed is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
ResMed
7 Very Positive mention(s)
1 Positive mention(s)
3 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Baxter International
2 Very Positive mention(s)
2 Positive mention(s)
4 Neutral mention(s)
1 Negative mention(s)
0 Very Negative mention(s)
Neutral

ResMed has a beta of 0.64, suggesting that its stock price is 36% less volatile than the S&P 500. Comparatively, Baxter International has a beta of 0.64, suggesting that its stock price is 36% less volatile than the S&P 500.

Summary

ResMed beats Baxter International on 11 of the 19 factors compared between the two stocks.

Get ResMed News Delivered to You Automatically

Sign up to receive the latest news and ratings for RMD and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding RMD and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

RMD vs. The Competition

MetricResMedSurgical & medical instruments IndustryMedical SectorNYSE Exchange
Market Cap$32.32B$3.93B$5.11B$18.05B
Dividend Yield0.87%1.96%43.85%3.43%
P/E Ratio33.5712.81148.0023.97
Price / Sales7.6069.782,361.3710.29
Price / Cash28.1747.9936.6420.14
Price / Book6.934.865.766.01
Net Income$897.56M$4.48M$104.93M$966.25M
7 Day Performance2.22%2.02%1.87%1.87%
1 Month Performance23.06%3.39%4.76%7.16%
1 Year Performance-2.52%18.57%7.73%21.68%

ResMed Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
BAX
Baxter International
4.7992 of 5 stars
$35.23
-0.6%
$45.73
+29.8%
-17.6%$17.95B$14.81B6.7860,000
DXCM
DexCom
4.8498 of 5 stars
$125.97
+0.8%
$141.67
+12.5%
+10.8%$50.10B$3.62B81.279,600Analyst Upgrade
Short Interest ↓
Positive News
PODD
Insulet
4.9445 of 5 stars
$172.27
+7.0%
$239.44
+39.0%
-40.2%$12.06B$1.70B52.203,000High Trading Volume
TFX
Teleflex
4.8237 of 5 stars
$212.62
+2.7%
$261.75
+23.1%
-11.3%$10.01B$2.97B34.1314,500Ex-Dividend
GMED
Globus Medical
4.4254 of 5 stars
$62.87
-1.4%
$66.50
+5.8%
+13.4%$8.51B$1.57B98.245,000Insider Selling
Short Interest ↑
BDX
Becton, Dickinson and Company
4.92 of 5 stars
$235.00
-0.8%
$281.40
+19.7%
-6.0%$67.92B$19.37B51.7673,000Insider Selling
Short Interest ↓
News Coverage
BSX
Boston Scientific
4.3282 of 5 stars
$73.47
+0.9%
$75.09
+2.2%
+39.8%$107.79B$14.24B61.7448,000Analyst Forecast
Short Interest ↑
SYK
Stryker
4.8621 of 5 stars
$324.30
-0.1%
$365.94
+12.8%
+17.9%$123.54B$20.50B37.0252,000
WST
West Pharmaceutical Services
4.8662 of 5 stars
$354.48
-1.0%
$435.20
+22.8%
+2.2%$25.82B$2.95B46.7710,600Analyst Revision
Positive News
SWAV
Shockwave Medical
4.4435 of 5 stars
$331.00
+0.2%
$309.11
-6.6%
+19.3%$12.43B$730.23M77.341,468Positive News

Related Companies and Tools

This page (NYSE:RMD) was last updated on 5/18/2024 by MarketBeat.com Staff

From Our Partners